Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

J&J gets EMA nod for wider use of Erleada in prostate cancer

Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and

Latest news

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
Litigation concerns threaten to overshadow solid quarter at J&J

therapy Zytiga (abiraterone acetate).
Lynparza scores another positive phase 3 prostate cancer study

Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide).
J&J puts pressure on rivals with new Erleada okay in prostate cancer

Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer therapy Zytiga (abiraterone acetate), which has been in a market battle for years with Xtandi
Trial backs role for Lynparza in second-line prostate cancer

In the 340-patient trial, Lynparza was compared to hormonal treatment with Pfizer’s Xtandi (enzalutamide) or Johnson &Johnson’s Zytiga (abiraterone acetate) in this second-line setting, focusing on patients

More from news
Approximately 5 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

RWE Blog 1: Real-world challenges and real-world data

Real-world patients treated with abiraterone for post-chemotherapy metastatic castration-resistant prostate cancer survived longer with shorter treatment duration compared with patients in clinical trials.
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Abiraterone. Zytiga. Janssen. Treatment of patients with metastatic castration-resistant prostate cancer. .

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...